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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre (IDRC) over the period Nov 2015 to April 
2016 to inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The 
LVIF is a seven-and-a-half year, CA$57 million partnership between the Bill & Melinda 
Gates Foundation, Global Affairs Canada and Canada’s International Development 
Research Centre. It focuses on those animal diseases posing the greatest risk to poor 
livestock keepers in Sub-Saharan Africa, South and Southeast Asia, targeting 
transboundary diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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Although the main focus of the present monograph is Hemorrhagic septicemia, diseases caused by bacteria of 
the genus Pasteurella, namely Mannheimia haemolytica and Pasteurella multocida in cattle, sheep and goat are 
of great importance especially in Africa, where large number of vaccine doses are sold annually. Unfortunately, 
most of the time these vaccines do not match the circulating strains, due to limited or lack of diagnostic and 
typing capacity, or do not include key components like leukotoxins. These other Pasteurellosis will also be 
covered in this monograph when possible.  
 
Disease, etiology, epidemiology and impact 
Hemorrhagic septicemia (HS) is an acute, often fatal and septicemic disease of mainly cattle and buffaloes, 
caused by P. multocida. It is important in tropical regions of the world, especially in Asian and African countries.  
HS epidemics are devastating, and jeopardize not only the economic return of animal production, but more 
importantly, animal traction, and the harvest of vital crops such as rice.  Cattle and buffalo are the major 
reservoir hosts. Outbreaks have been reported occasionally among pigs in some Asian countries, and cases are 
seen infrequently in sheep and goats.  HS is caused by two serotypes of P. multocida designated B:2 (Asian 
serotype), and E:2 (African serotype; although in some African countries, B types have also been isolated).   
Cattle and buffaloes, reared mainly as draught animals but also for milk production, are mainly affected. 
Buffaloes have a shorter course of disease and are believed to be more susceptible.  Natural infections are 
generally by inhalation and/or ingestion of contaminated materials.  HS is endemic in many countries. In 
endemic areas, most deaths are in older calves and younger adults. In non-endemic areas, massive epizootics 
occur.  
A detailed study conducted recently in India, revealed that the morbidity losses account for 23% of the total 
losses and 77 % are due to mortality. The total economic loss per infected animal due to HS was estimated at Rs 
6816 (USD 102) in case of cattle and Rs 10,901 (USD 163) in buffalo. These losses when scaled-up at the national 
level have indicated a loss of Rs 5,255 crore (Rs 52,550 million – USD 785 million). A different but also recent 
study, estimated mortality losses per animal at Rs 27,467 (USD 410) and Rs 31,901 (USD 476) for indigenous and 
local buffalo respectively. 
 
Other pasteurellosis 
 The nomenclature of the genus Pasteurellaceae has been changing, and that has created and still creates some 
confusion. Annex 2 shows the old and new names. Besides HS caused by P. multocida, the other key diseases in 
ruminants caused by bacteria of the genus Pasteurellaceae are: 1- Bovine Pneumonic Pasteurellosis (BPM) 
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caused mainly by Mannheimia haemolytica A1 and less frequently by P. multocida A, 2- Pneumonic 
pasteurellosis of sheep and goats, caused mainly by M. haemolyitica (usually A2) and 3- Septicemic 
pasteurellosis in sheep, caused by Bibersteinia trehalosi (Table 1).   
 
Incidence / Prevalence 
HS has a wide distribution with the highest occurrence in South East Asia. The disease is important in Africa, the 
Middle East and some countries in southern Europe. Incidence and distribution of HS vary greatly from a few 
cases to high numbers depending on the type of husbandry practices, geographical area and agro-climatic 
conditions prevailing in a particular region. Except for Bangladesh and India, there seems to be little information 
on HS available at country level (for the countries of interest) but more information might be locally available (in 
local languages).  
 
DIagnostics 
The diagnosis of HS depends on the isolation of the causative organism, P. multocida, generally from the blood 
or bone marrow of a dead animal by cultural and biological methods, and the identification on the organism by 
biochemical, serological and molecular methods. Conventionally, the identification of the serotype is carried out 
using one or more serological methods.  Molecular techniques can be used for capsular typing confirmation 
(currently not available for somatic typing).  Most African countries have difficulties in typing, and therefore 
matching the field strains to the vaccines, but this diagnostic capability has not been explored by country as it 
was beyond the remit of this monograph, despite that it has a huge impact on the effectiveness of vaccines.  
 
Control 
Treatment is of little use once signs of HS have appeared, but could be effective in the early stages. However, 
treatment is constrained by a variety of practical considerations. Generally, clinical cases are treated with 
oxytetracycline, co-trimoxazole, a combination of penicillin and streptomycin or sulphaquinoxaline. In recent 
times, a gradual development of resistance has been observed. 
Sanitary control measures include early detection and isolation of new cases and their immediate treatment 
with antibiotics, deep burial of carcasses or incineration, and the prevention of movements of animals to disease 
free areas.  Vaccination of susceptible animals in endemic areas is the only practical approach to prevent HS.   
Measures to be adopted in endemic countries on a prophylactic basis, in the event of an outbreak, and 
measures necessary for prevention of spread across regional or national borders are discussed in Section 5. No 
country has ever attempted to eradicate HS. This reflects the belief that the existence of carriers makes 
eradication too hard.  Of the countries of interest, only Mali has said HS is a notifiable disease.  
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Current vaccines for HS 
Vaccination is the most efficient and cost-effective method to control HS. Although the available vaccines are 
effective in providing protection, disease outbreaks still occur due to low vaccination coverage, particularly of 
animals kept extensively.  
Simple bacterins for P. multocida protect relatively well, as they are based on the capsule of P. multocida. The 
OIE recommends to use a local isolate of P. multocida representing the prevalent serotype. Seed cultures for 
vaccine production should contain capsulated organisms. 
The commonly used HS vaccines are bacterins: alum-precipitated vaccines (APV), aluminum hydroxide (AlOH) gel 
vaccines, and oil-adjuvanted vaccines (OAV).  To provide sufficient immunity with bacterins, repeated 
vaccination is required.  Administration of dense bacterins can give rise to shock reactions, which are less 
frequent with the APV and almost nonexistent with the OAV. The APV provides immunity for 6 months, while 
the OAV provide immunity for up to 1 year.  However, the OAV have not been popular because of their high 
viscosity making it difficult to use.  
A live attenuated vaccine administered intranasally has been used extensively in Myanmar. It was recommended 
by the Food and Agriculture Organization of the United Nations (FAO) as a safe and potent vaccine for use in 
Asian countries. However, there are no reports of it being used elsewhere.  
Vaccine potency:  The OIE recommends back passaging of the master seed in calves before producing the 
vaccine (only subculture once or twice).  It has been demonstrated that back passaged vaccine seed provides 
better immune efficiency than the original stock culture, and therefore it is recommended the back passaging of 
the seed vaccine at least once in 6 to 8 months in calves, which is laborious and expensive.  
Cross protection: The protective immunity for P. multocida resides in the capsule. There is very little, if any cross 
protection between capsule types. More recent studies also question role of LPS polymorphism in vaccine failure 
in poultry (not studied for HS). It is interesting to note, that some of the commercial vaccines produced in Africa 
for HS, seem to have the B (Asian) serotype, instead of the E (African) serotype, and some other do not specify 
the serotype used. This might be a potential reason for vaccine failure.  
 
Commercial vaccines for other pasteurellosis 
Bovine pneumonic pasteurellosis: Vaccines based on virulence factors like leukotoxins (Lkt) seem to work better 
than vaccines based on serotypes, as the Lkt from cattle is relatively homogenous (the Lkt protects against M. 
haemolytica, not against P. multocida). Other vaccines have been developed based on iron regulated proteins, 
and outer membrane proteins (OMP). The iron-regulated proteins are related to the serotype. A better 
protection is shown if the iron-regulated outer proteins are derived from a number of different strains, and 
there is some cross-protection between unrelated strains. Modern vaccines use culture supernatants containing 
leukotoxin (Lkt) and other soluble antigens, or bacterial extracts, alone or combined with bacterins.  Some 
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vaccine manufacturers claim that Lkt based vaccines protect cattle against nearly all M. haemolytica infections. 
But others say that these modern vaccines have 50–70% efficacy in prevention of M. haemolytica pneumonia. It 
is interesting to note that the majority of African vaccine manufacturers do not mention the inclusion of Lkt or 
other proteins, while the international pharmaceutical companies include them in all their vaccines. From the 
information collected, only OBP (South Africa) produces a Lkt based vaccine in Africa. If they are not included in 
the current African vaccines, it might be valuable to consider their incorporation to improve efficacy.  
It has also been noted that the use of the name pasteurellosis creates confusion. For example, one country 
replied in the questionnaire that they are importing a P. multocida based vaccine for control of BPM, which 
would not be effective, as it is not based on M. haemolytica. 
 
Pneumonic pasteurellosis of small ruminants and Septicemic pasteurellosis of sheep:  Because sheep strains 
show much more variability between different strains of any single serotype, leukotoxin type vaccines do not 
work as well as they do in cattle. The existing leukotoxin vaccines are based on the cattle M. haemolytica A1 
strain of the Lkt, which may be the same or may differ from the Lkt of the strain which is infecting the sheep. 
Serotype based vaccines, seem to work better in sheep.  There are only 4 commercial vaccines for small 
ruminants produced in Africa. Two of them are based on P. multocida only so their efficacy is questionable.  Only 
one contains B. trehalosi, the cause of septicemic pasteurellosis.  
A big multinational pharmaceutical company manufactures a vaccine for sheep based on iron-regulated 
proteins, which contains 9 serotypes and is available in South Africa.  
In the databases researched, there was no mention of BPM or small ruminant pasteurellosis vaccines produced 
in Asia.   
 
Potential new vaccines and the way forward 
For the control of HS, vaccines with longer duration of immunity, easy to use and with no side effects would be 
desirable. Characteristics of an ideal HS vaccine, can be seen under the Target Product Profile in Section 9.  
Live attenuated vaccines look promising, as they would overcome some of the issues.  Would be good to 
understand why the strain used in Myanmar hasn’t been used elsewhere. There have been developments on 
live attenuated strains in Iran, in Malaysia and UK.  Unfortunately, none of the researchers provided an update 
on their developments.  As for DIVA vaccines, the candidate from Dr Saxena looks interesting, but detailed 
evaluation of the technical information is needed (not published yet). The candidate from Prof Singh, has not yet 
been evaluated in the target species and also needs detailed analysis of the technical data.  
There are groups working on DNA and sub-unit vaccines, but they seem far from commercialization.  There is 
also a group working on improved delivery system with nanoparticles.  
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Besides all the new technologies, there is a great need for improvement of the currently used vaccines (ensuring 
use of the correct serotype, back passaging in calves, etc.), especially on the African continent.  Most of the 
African vaccine manufacturers do not have Pasteurella typing capacity (capsular and somatic typing capacity). If 
properly empowered and capacitated, AU-PAVAC could provide the required serotyping service to all vaccine 
manufacturers. AU-PANVAC has also expressed the need in capacity building of the African vaccine 
manufacturers in bacteriology aspects which goes beyond Pasteurella (for example there is a need to train the 
labs in terms of isolation and characterization of the local strains of clostridum for Black leg vaccine).  This would 
seem less of a challenge in Asia but needs to be confirmed.  
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Etiology & Epidemiology 
 
Historically, the term pasteurellosis has been used to indicate disease caused by bacteria of the genus 
Pasteurella. The genus Pasteurella is a member of the Pasteurellaceae family, which includes a large and diverse 
group of Gram-negative Gammaproteobacteria, whose members are not only human or animal commensals 
and/or opportunistic pathogens but also outright pathogens. Ancestral relationships among bacterial taxa within 
the Pasteurellaceae family can be inferred by comparing their 16S rRNA genes (See Annex 1). Comparative 
genomic and phylogenetic analyses of the Pasteurellaceae have revealed that many members of this highly 
diverse family were poorly classified. Indeed, a number of the Pasteurellaceae have already been renamed 
including Mannheimia (formerly Pasteurella) haemolytica in 1999 and Bibersteinia (formerly Pasteurella) 
trehalosi which was renamed in 2007.  However, as can been seen from the 16S rRNA phylogenetic tree shown 
in Annex 1, further reclassification or renaming may be warranted [1].  Current and old names are shown in 
Annex 2.  
Although the reclassification makes continued use of the term pasteurellosis awkward, new terms have not 
emerged yet.  Table 1 shows the different diseases in cattle and small ruminants with the causative agents.  
P. multocida isolates are classified based on a combination of capsular polysaccharide serotyping, which 
distinguishes isolates into one of the five capsular serogroups A, B, D, E and F, using indirect hemagglutination. 
Isolates are also subtyped based on their lipopolysaccharide (LPS), which separates isolates further into 16 
serovars using the agar gel immunodifusion test. Isolate designations usually consist of a capsular serogroup 
letter followed by a somatic serovar number (e.g., A:1, A:2, A:3, B:2, etc.).  
Table 1: Feasibility of OIE recommended sanitary control measures in smallholder poultry settings. 
 
Host species Disease Organisms involved (most commonly) 
Cattle & buffalo 1- Hemorrhagic septicemia • Africa: Mainly Pasteurella multocida E:2  
• Asia: Pasteurella multocida B:2  
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Pathogenomics of P. multocida 
The genomes of six different P. multocida have been sequenced, three from poultry, two from pigs and one from 
cattle. For cattle, the strain P. multocida 36950 was obtained from the lung of a bovine with respiratory 
infection. A number of genes or gene clusters, have been implicated as important for virulence of P. multocida. 
Some of these genes encoding putative virulence factors are universally present in all six P. multocida. These 
include genes encoding outer membrane proteins (ompA, oomph and ompW), iron acquisition proteins (exbB-
exbD-tonB, hgbA, and fur), thiamine metabolism proteins (tbpA, thiP, and thiQ), and the adhesion/Flp pilus 
assembly cluster (tadZABCDEFG). Homologs of the tad gene locus are also present in many other 
Pasteurellaceae and Gram-negative bacteria, where they play key roles in biofilm formation, colonization, and 
pathogenesis.  
Unique genes correlated with virulence are present in almost each of the sequenced P. multocida genomes. For 
instance, P. multocida strain 36950, contains the large integrative conjugative element (ICE) ICEPmu1 of 82 kbp 
that carries 88 genes, including 12 antimicrobial resistance genes. This ICE is not found in any of the other five 
sequenced genomes; however, a similar ICE was found in Histophilus somni 2336 and Mannheimia haemolytica 
PHL213, both of which are bovine respiratory pathogens and thus share the same host niche as P. multocida 




Pasteurella species cause numerous endemic and epizootic diseases of economic importance in a wide range of 
domestic and wild animals and birds. P. multocida is a common commensal or opportunistic pathogen found in 
the upper respiratory tract of most livestock, domestic and wild animals. Under stress conditions, the 
commensal P. multocida becomes a pathogen by overwhelming the immune system of the host, proliferating in 
the nasopharynx and spreading to the lungs.  The clinical signs vary from asymptomatic or mild chronic upper 
Cattle 2- Pneumonic pasteurellosis or 
mannheimiosis (Shipping fever, bovine 
enzootic pneumonia) 
• Mannheimia haemolytica A:1 (main cause) 
• Pasteurella multocida A (less frequently involved) 
Sheep & goats 3- Pneumonic pasteurellosis • Mannheimia haemolytica (mainly A:2) 
4- Septicemic pasteurellosis • Bibersteinia trehalosi (used to be called Pasteurella 
trehalosi and before P. haemolytica T) 
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respiratory inflammation to acute, often fatal, pneumonic and/or disseminated disease.  The main diseases 
caused by the genus Pasteurella in cattle and small ruminants are:  
• 1-Hemorrhagic septicemia (HS): Is a major disease of cattle and buffaloes characterized by an acute, highly 
fatal septicemia with high morbidity and mortality (both vary between 50 and 100%). These two species are 
also the major reservoir hosts. Outbreaks have been reported occasionally among pigs in some Asian 
countries, and cases are seen infrequently in sheep and goats. Goats have been infected experimentally. HS 
has also been reported in bison, African buffalo, camels, elephants, horses, donkeys and yaks. Experimental 
infections are readily established in laboratory rabbits and mice.  HS is caused primarily by serotypes B:2 and 
E:2 (Carter and Heddleston system), corresponding to 6:b and 6:E (Namioka-carter system). In Africa it is 
associated to P. multocida type E:2 but some African countries have also reported B:2 (Namibia in 1997, 
Cameroon in 1993 and Zimbabwe in 1990). In Asia, the only reported serotype is B:2. HS may be 
asymptomatic until the onset of the acute stage, which is characterized by a rapid onset and progression. 
Symptoms include fever, lethargy, edema, copious salvation, lacrimation, and nasal discharge, followed by 
respiratory distress, septic shock with widespread hemorrhaging, and death within 1-3 days. Buffaloes have 
a shorter course of disease, and are generally believed to be more susceptible than cattle. Animals between 
the ages of 6 and 24 months are the most severely affected during outbreaks. There are direct losses 
associated to mortality, but also indirect losses associated to loss of productivity, milk, meat, draught power, 
cost of alternate sources of draught power and impairment of the reproductive potential.  HS is endemic in 
the tropical and subtropical regions the world including Asia, India, the Middle East and Africa.  In endemic 
areas, most deaths are confined to older calves and younger adults. In non-endemic areas, massive 
epizootics occur. Case fatality approaches 100%, if treatment is not carried at an earlier stage. 
• 2- Bovine pneumonic pasteurellosis or mannheimiosis (BPM): M. haemolytica is the main agent responsible 
for BPM.  It is an acute fulminating, fibrino-purulent pleuropneumonia with hemorrhage or coagulation 
necrosis, due to intense LPS-induced inflammation and production of a ruminant-specific leukotoxin. It is an 
economically significant disease of cattle, accounting for about 30% of the total cattle death in the world.  
M. haemolytica type A exists in 12 different serotypes (1-17 except 3, 4, 10, 11 and 15).  A1 and A6 are the 
most frequent isolates from pneumonic lungs [2]. Several serotypes have been isolated in Africa: Kenya 
reported predominance of serotypes A1 and A2 (1978), and South Africa (1995) 30% untypable and 40% A1.  
Also serotypes 14, 6, 2 and 15 were identified. 
• 3- Pneumonic pasteurellosis in small ruminants:  Small ruminants are particularly susceptible to respiratory 
infections complicated by M. haemolytica and it is the most common form of respiratory disease in sheep 
and goats. The disease occurs worldwide in temperate, subtropical and tropical climates, although the 
prevalence of serotypes may vary by region and flock.  Serotype A2 is a common cause of pneumonic 
pasteurellosis in sheep, but there is also an increased prevalence of serotypes A5, A6 and A7 [2]. In South 
Africa, in a study done in 1995, serotype 6 was the most prevalent, followed closely by types 9 and 2 [3].  
• 4- Septicemic pasteurellosis in sheep: B. trehalosi causes systemic pasteurellosis only in sheep and the main 
feature is sudden death. It exists in 4 serotypes, T3, T4, T10 and T 15.  
Hemorrhagic septicemia | Monograph 17 








Is through direct contact with nasal secretions, where a chronic infection ensues in the nasal cavity, paranasal 
sinuses, middle ears, lacrimal and thoracic ducts of the lymph system and lungs.  The organism is capable of 
surviving in moist soil and water for up to 2-3 weeks. Preexisting or coinfection with other respiratory 
pathogens, particularly Bordetella bronchiseptica or Mannheimia haemolytica, significantly enhances 
colonization by P. multocida, leading to more severe disease. 
Primary infection with respiratory viruses or with Mycoplasma species also predisposes animals to secondary 
infection with P. multocida and/or M. haemolytica. Environmental conditions, stress, and the overall health of 
the animal also appear to play important roles in disease severity and likelihood of transmission 
In endemic areas, large numbers of animals that survive after an outbreak become latent carriers. They 
intermittently shed the organisms but, since the herd immunity is also high, there are no new clinical cases. A 
new outbreak occurs when a shedder comes into contact with a susceptible animal, which may be one born 
after the previous outbreak or one introduced into the herd. The chance of a new outbreak increases with time 
with an increase in size of the susceptible population. 
Once the first clinical case occurs, more bacteria are shed and disseminated. Their survival in the environment 
and transmission to other animals depend on factors such as closeness of contact, hygiene and climate (wet 
conditions prolong the survival of the causative bacteria outside the animal, making an outbreak more likely). 
Occasional sporadic outbreaks allow the build-up of nonimmune animals and a major outbreak may occur. 
Regular seasonal outbreaks result in much higher herd immunity (through frequent exposure) and outbreaks 




Until very recently, conventional methods for detection and diagnosis of infection with Pasteurella relied on the 
isolation of the bacteria from the blood or bone marrow of a dead animal, and observation by microscopy using 
staining and/or isolation by in vitro culturing on selective media, followed by phenotypic and/or serological 
characterization.  
Phenotypic characterization of P. multocida, based on morphology, carbohydrate fermentation patterns, and 
serology, is challenging. Identification of P. multocida using biochemical strips (such as API 20E/20NE, Minitek, or 
Oxi/Ferm strips) remains a rapid method commonly used in diagnostic laboratories, but it has limited accuracy 
and can lead to confusion of P. multocida with Mannheimia (Pasteurella) haemolytica, H. influenzae, or other 
Pasteurellaceae species. 
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Several serotyping tests are used for the identification of the HS-causing serotypes of P. multocida. Capsular 
typing can be done by rapid slide agglutination, indirect haemagglutination, agar gel immunodiffusion tests 
(AGID) and counter immunoelectrophoresis.  Somatic typing can be done by AGID and other tests.  
Hyperimmune antisera for most of these tests, are prepared against specific reference strains in rabbits.  
PCR- plus sequence-based ribotyping analysis using universal primers for 16S rRNA genes, genomics, and other 
DNA sequence based molecular techniques have now superseded phenotypic methods for identification, 
characterization, and differentiation of P. multocida and other Pasteurellaceae. Conventional ribotyping based 
on PCR amplification alone is still generally considered a reliable and discriminative method for characterizing 
clinical isolates of P. multocida. However, PCR amplification of 16S rRNA genes, followed by sequencing and 
sequence comparison against known ribosomal databases, such as the NCBI or the RDP 
(http://rdp.cme.msu.edu) database, is now the predominant and most reliable method of taxonomically 
identifying isolates at the genus and species levels. The OIE mentions multiplex capsular PCR typing systems, and 
type-B and type A specific PCRs. Molecular techniques for somatic typing don’t seem to be available.  
A loop-mediated isothermal amplification assay (LAMP) has been developed for the identification of P. 
multocida of pigs [4]. Bhimani and colleagues in 2015, used newly designed primers to identify P. multocida in 
cases of HS, and they demonstrated to be a more sensitive test than PCR [5]. LAMP is a rather newer molecular 
technique, which can be used for rapid detection of the infectious agent at field level and which does not 
require sophisticated instruments, i.e. thermal cycler. LAMP requires lesser time than a conventional PCR to 
perform (the reaction time took only 30 minutes), and results can be read visually.  Data on LAMP has also been 
reported by Moustafa and Bennet in 2014 (http://pasteuraceae-2014.p.asnevents.com.au/days/2014-05-
15/abstract/12799). 
 
OIE listed tests: 
Identification of the agent:  
• Cultural and biochemical methods 
Serotyping: 
• Rapid slide agglutination test (capsular typing) 
• Indirect haemagglutination (capsular typing) 
• Agar gel immunodiffusion tests (capsular and somatic typing) 
• Counter immunoelectrophoresis – a rapid method for the identification of capsular types B and E 
cultures.  
• Agglutination tests (somatic antigen) 
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Nucleic acid recognition methods 
• P. multocida specific PCR assay 
• P. multocida multiplex capsular PCR typing system 
• HS-causing type-B-specific PCR assay 
• P. multocida type A specific PCR 
Serological tests (for the detection of antibodies): are not normally used for diagnosis.  
 
Serotyping in Africa:  Dr Marijke Henton from IDEXX South Africa (personal communication), said that she used 
to type both Mannheimia and Pasteurella whilst she was at Onderstepoort, and prepare the antisera as well. 
There appears to be no commercial sources for typing sera, and since she left Onderstepoort in 2002, the typing 
of both has fallen into disuse? Disrepair? Anyhow, no fresh sera have been prepared since that time.  Many 
African laboratories including AU-PANVAC do capsular typing by PCR, but have no capability for somatic 
serotyping (Nick Nwankpa, AU-PANVAC personal communication). 
Serotyping is critical for sheep vaccines, as all the available sheep vaccines are still serotype based. Serotyping of 
isolates is currently the only way to match up the problem on the farm with an available vaccine. 
Differential diagnosis 
The differential diagnosis of HS includes other causes of sudden death such as lightning strikes, blackleg 





There are no reports of human infections with P. multocida serotypes B:2 and E:2; however, other serotypes do 
infect humans, and precautions should be taken to avoid exposure.  Humans acquire Pasteurella infection 
primarily through contact with animals, most usually through animal bites, scratches, licks on skin abrasions, or 
contact with mucous secretions derived from pets.  A survey of the literature over the past 30 years suggests 
that 20 to 30 human deaths due to pasteurellosis occur annually worldwide [1]. Among the Pasteurella species, P. 
multocida is the predominant human pathogen encountered, especially in severe disease cases although P. canis 
may be more prevalent with dog bites. 
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Hemorrhagic septicemia has a wide distribution with the highest occurrence in South East Asia. The disease is 
important in Africa, the Middle East and some countries in southern Europe. It has also been recognized in Japan 
and North America. The African form of HS occurs sporadically, it is limited in extent and appears to be 
associated with stress conditions. The B:2 serotype has been reported in southern Europe, the Middle East, 
South East Asia and North America. The E:2 serotype occurs primarily in Africa but Namibia, Cameroon and 
Zimbabwe have also reported serotype B. Both B and E serotypes have been reported in the Sudan and in Egypt. 
Neither serotype has been found in South America, Central America, Australia or New Zealand. 
 
It is important to note that Table 2 includes South Africa as endemic, but the disease is very rare. In Southern 
Africa the disease is very sporadic, and mainly restricted to the wetter subtropical regions of Zambia, Zimbabwe 
and the northern parts of Namibia.  
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Incidence data by country 
There are two main sources, OIE and AU-IBAR (which includes only Africa), but data are not always similar.   
1- Source: OIE.   
Data of outbreaks reported to the World Animal Health Organization (OIE) are shown in Tables 3 and 4.  Data are 
not always reliable, as many countries dosn’t seem to report, or report inconsistently over time.   
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
Similar information presented in a different manner can be seen in Annex 3.   
Number of cases reported to the OIE by disease and by country: 
     -   No information,      +   Present but quantitative data not known,   ?  Disease suspected 
 
Table 3:   ASIA – Hemorrhagic septicemia outbreaks notified to OIE from the Asian countries of interest.  
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - + + + + + + + + - 
India 775 770 470 359 296 380 315 248 135 131  
Indonesia + + + + + + + + + - - 
Myanmar + >2 27 9 10 3 7 2 5 >1 - 
Nepal 374 >215 11 >68 126 113 165 82 52 58 21 
Vietnam 553 1,309 1,673 2193 536 239 163 192 116 130 70 
 
 
Table 4:    AFRICA - Hemorrhagic septicemia outbreaks notified to OIE from the Asian countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso 33 24 28 33 41 64 39 23 12 18 >9 
Ethiopia 53 998 404 349 400 566 370 491 498 154 - 
Ivory Coast - - - - - 6 4 3 0 0 0 
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2- Source: AU-IBAR. 
Number of outbreaks per year as reported to AU-IBAR and published in the Pan African Animal Resources 
YearBook. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=)  
Table 5 shows the number of pasteurellosis outbreaks reported to AU-IBAR, but interpretation should be done 
with caution. Reporting of Pasteurellosis from AU-IBAR has varied over time.  Some years they reported only HS 
(2007), for some years there are no details (2008, 2009), and in the later years there seem to be a distinction 
between HS and other pasteurellas.   
Kenya 0 0 0 0 0 0 0 0 0 0 0 
Madagascar 0 0 0 0 0 0 0 0 0 0 - 
Malawi - - - - 0 0 0 0 - - - 
Mali 0 0 - - - 0 0 0 0 1 1 
Mozambique 0 0 0 0 0 0 0 0 0 0 - 
Rwanda - - - ? - - - - - - - 
Senegal 34 11 7 9 7 11 8 ? 7 6? 3 
South Africa 0 0 0 ? 0 2 1 0 0 0 - 
Tanzania + >9 13 >1 + + + + + 2 2 
Uganda - - - - - - - - - - - 
Zambia - 16 13 30 48 43 + 14 21 26 - 
 
 
Table 5: Number of Pasteurellosis outbreaks per year as reported to AU-IBAR and published in the Pan 
African Animal Resources YearBook.  Please see notes below the table for each year. NS= Not specified  
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso 16 48    63 40 23 18 18  
Ethiopia      769 570 718 1,063 292  
Ivory Coast      7  5    
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2005: A total of 1,230 pasteurellosis outbreaks were reported in 6 countries, and were restricted to bovine, 
caprine and ovine.  
2006: Seven African countries reported 106 outbreaks of pasteurellosis.  Bovines were most affected, followed 
by small ruminants.  
2007:  It is noted that the report is on HS.  4 member countries reported a total of 27 outbreaks.  
2008: 2,410 pasteurellosis outbreaks from 15 countries were reported to AU-IBAR but no details are given.  It 
says 4 countries reported HS, but no details are given either.  
2009: 416 outbreaks of pasteurellosis were reported, and 132 outbreaks of HS.  
2010:  994 outbreaks were reported from 23 countries.  
2011: 13 countries recorded a total of 1,016 outbreaks. Additionally, 3 countries reported HS (no details).  
2012: 18 countries reported HS and other pasteurellosis, with a total of 1257 outbreaks.   
Kenya            
Madagascar  1    NS 7     
Malawi            
Mali 3     2   1 1  
Mozambique      2      
Rwanda            
Senegal 1 23 15   30 14 7 4 5  
South Africa      4  1  2  
Tanzania        1  1  
Uganda            
Zambia      21 11 10 22 21  
 
Reported as Pasteurellosis, no details given.  
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2013: 10 countries reported HS and other pasteurellosis, with a total of 1,211 outbreaks. It is clear that the 10 
outbreaks relate to HS.  
2014: 14 countries reported HS and other pasteurellosis, with a total of 391 outbreaks. The report makes clear 
that Mali, Senegal and South Africa are not HS, but other pasteurellosis. HS was reported in 9 countries, and 




Outbreak data by country 
Incidence and distribution of HS vary greatly from a few cases to high numbers depending on the type of 
husbandry practices, geographical area and agro-climatic conditions prevailing in a particular region [6]. 
Outbreaks of disease occur throughout the year irrespective of the season.  This is in contrast to the perception 
that the disease is mostly precipitated during the monsoon or post-monsoon period.  
 
Bangladesh 
Number of outbreaks reported based on passive surveillance 2010-2012 [6]: 
• 2012: 4,769 
• 2011: 5,885 
• 2010: 2,782 
 
India 
In India, the incidence of disease outbreaks varies considerably in different states and from year to year in each 
state [6]. 
2014:  There were 93 outbreaks of HS in bovines (304 dead animals), 32 outbreaks in buffaloes (201 animals 
dead), and 6 in ovine/caprine (6 animals dead).  Source: Annual report 2014-2015. Department of Animal 
Husbandry, Dairying & Fisheries, Ministry of Agriculture, Government of India. 
http://dahd.nic.in/dahd/WriteReadData/Animal%20Husbandry%20English%202014-15%20(1).pdf 
1991 – 2010: A epidemiological study was conducted by the Project Directorate on Animal Disease Monitoring 
and Surveillance (Bengaluru) in 2012. It showed a constant variation in the number of states reporting HS. Also a 
progressive trend was seen in occurrence of HS since 1992. Maximum outbreaks were reported in 1998. There 
has been a gradual decline in HS outbreaks since 1998 and many states reported fewer outbreaks during 2006-
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2010. The decline in the occurrence can be attributed to the availability of cost-effective programs for 
prevention and control. Many districts of Madhya Pradesh, Odisha and Rajasthan have reported the disease for 







Figure 1: Status of HS in India. (Source: PD-ADMAS/ TECHNICAL BULLETIN/ 11 / 2012) 
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The disease has been reported in Java Rhinoceros. http://www.livingfossil.org/science/javan-rhino.php  
Gayo Leus District:  690 deaths have been reported 2013 – early 2015, in 11 sub-districts.  The majority of the 




No country specific information was found on PubMed or the internet.  
 
Nepal 
No country specific information was found on PubMed or the internet.  
 
Vietnam 
No country specific information was found on PubMed or the internet.  
 
No data has been found for the African countries of interest.  
 
Prevalence data by country 
 
Bangladesh 
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Table 6: Estimated number of diagnosed cases, prevalence, death cases and vaccination coverage of 






The majority of the data found was on number of outbreaks. Only one article was found on prevalence, in the 
province of Uttar Pradesh. 
http://www.indianjournals.com/ijor.aspx?target=ijor:abr&volume=13&issue=2&article=009 
The presence of antibodies against P. multocida B:2 in 10 (22.2%) serum samples by CIE showed the prevalence 
of P. multocida B:2 infection in the area. 
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Economic and Social Impacts at Global 







HS is a disease of utmost economic importance particularly in Asia and to a lesser extent in Africa. Few countries 
have attempted to quantify the losses due to HS, and there is no uniformity in the methods adopted. Thus, these 
studies are not strictly comparable, but reflect the trends. Most of the available information is derived from 
passive reporting systems. 
Most estimates of losses take into account only direct losses, i.e. value of animals that die of HS. A true estimate 
of losses should take into account a variety of factors which constitute indirect losses, including: 
a) Loss of productivity – milk, meat, draught power, and cost of alternate sources of draught power. 
b) Impairment of the reproductive potential of the animals. 
c) A reliable differential diagnosis as there is tendency during the Monsoon to attribute any mortality to HS. 
Thus a possible over-estimation of these losses should be taken into account. However, it must also be kept 
in mind that reported losses constitute only a fraction of the actual losses. This is bound to be so since HS is 
a disease that occurs in situations where husbandry practices are poor and therefore disease reporting 
system will also be poorly developed. 
 
Asia 
A good review has been done in 2002 by Benkirane and De Alwis [8]. In Asia the susceptible animal population 
consisted of 432 million cattle and 146 million buffaloes at the time of the publication, which constituted 30% 
and 95% of the world’s cattle and water buffalo population, respectively. 
Milk production 
Cattle and buffaloes are reared mainly for use as draught animals in the rice fields, but in India and, to a lesser 
extent, Pakistan, milk production is also important (FAO 1994, 1995). In Asia as a whole, buffaloes contribute 
37% of milk production but in India, where the production of milk is the highest in Asia, nearly 50% of the milk is 
produced from buffaloes. 
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Most of the cattle and buffaloes are used as draught animals in the rice fields, and rice is the staple diet in many 
countries. Where animals are used for draught power, which is a seasonal activity, they are managed in an 
extensive, free-range system for most of the year. Such conditions are an ideal environment for the spread of 
diseases such as HS because herds of animals belonging to different owners roam together in common 
grasslands, drink in common village tanks and are often even paddocked together at night. Such animals are 
often less well managed, with lower vaccination coverage, than more intensively farmed animals. 
Thus, the high population of buffalo in Asia, the high susceptibility of buffalo to HS and the high case fatality, all 
point to the significance of the economic losses due to the disease (FAO, 1994, 1995). 
 
Individual country data 
In India, during the past four decades it has been found that HS accounted for 46–55% of all bovine deaths. 
During the twelve-year period since 1974 to 1986 it accounted for 58.7% of the aggregate of deaths due to five 
endemic diseases, with foot-and-mouth disease, rinderpest, blackquarter, anthrax and HS.  
• More recent data from the NIVEDI Annual report 2014-2015, mentions that in a study done by 
Govindaraj et al in three districts of Gujarat state (Ahmedabad, Mahisagar and Patan) showed an 
average case fatality rate among the local buffalo of 78%.  The estimated mortality loss per animal was 
Rs 27,467 (USD 410) and Rs 31,901 (USD 476) for indigenous and local buffalo respectively.  
• A detailed study conducted by Singh et al, and published in 2014 [9], revealed that the morbidity losses 
account for 23% of the total losses and the rest (77 %) are due to mortality of the animals. Of the total 
morbidity losses, about half have were due to reduction in growth and one-fifth due to loss in milk. The 
total economic loss per infected animal due to HS was estimated at Rs 6816 (USD 102) in case of cattle 
and Rs 10,901 (USD 163) in buffalo. These losses when scaled-up at the national level have indicated a 
loss of Rs 5,255 crore (Rs 52,550 million – USD 785 million). The direct losses contribute 80.3 % and 
indirect losses contributed 19.7 % to the total economic loss. The study has found that calves contribute 
74.8 % and adults contribute 25.2 % to the total economic loss due to HS.  
http://ageconsearch.umn.edu/bitstream/196991/2/12-B-Singh.pdf 
 
In an active surveillance study in Sri Lanka, it was shown that in the 1970‘s, around 15% buffaloes and 8% cattle 
in the HS endemic areas died of HS annually. During the same period, the passive reporting systems recorded 
only 1 200 to 1 500 deaths a year in a cattle and buffalo population of approximately 2.5 million. 
Pakistan reported that 34.4% of all deaths in susceptible stock is due to HS. In 2002, with a cattle and buffalo 
population of 17.7 and 18.8 million respectively, the annual economic losses were estimated at 1.89 billion 
rupees (350 million USD). In 2007, the HS prevalence was estimated at 49%. In 2010, there were about 29.9 
million heads of buffaloes in Pakistan.  
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In the South-East Asian region, countries such as Indonesia, Malaysia, Thailand, Myanmar, Laos, Cambodia and 
the Philippines, rank HS high among the economically important diseases of cattle and buffaloes.  
In Myanmar it is thought that 50% of the government’s effort in animal disease control is directed towards HS. 
Malaysia, with a relatively small population of 735,000 cattle and 186,000 buffaloes, estimates the animal losses 
due to HS to be 2.25 million Malaysian Ringit (0.85 million USD) (FAO, 1979). 
In a study in Bangladesh in 1996, an attempt was made to compute the economic losses resulting from three 
important endemic diseases, anthrax, blackquarter and HS. It was found that the direct losses which took into 
account the market value of the animals that died and the cost of treatment was 2.3 million US dollars. Their 
computation of indirect losses took into account the value of the rice that would have been produced from the 
land left uncultivated as a result of loss of draught power. These losses amounted to 148 million USD annually 
due to these three diseases. It may therefore be concluded that no accurate estimates are available on the 
actual deaths due to HS, and the available information on direct and indirect economic losses is incomplete.   
Verma and Jaiswal, mentioned in their paper published in 1998, recent reports of annual losses due to HS of 
approximately USD 1.4 million in Laos, and approximately USD 1 million in Malaysia [10]. 
 
Africa 
HS is of less economic importance in the African region than in Asia. This is because Africa has less of the world's 
cattle and buffalo populations. Also, many other animal diseases cause more severe economic losses. These 
include the African endemic diseases, such as trypanosomiasis (nagana), theilleriosis (East Coast fever) and 
contagious bovine pleuropneumonia. Published reports on economic losses in the African region are scarce. 
 
Analysis by the World Bank: 
The World Livestock Disease Atlas – a quantitative analysis of global animal health data [11], published by the 
World Bank (with cooperation of OIE and FAO) in 2011 is an attempt to understand which livestock diseases 
cause the heaviest losses, which countries suffers the worst disease-related losses and which livestock species 




The World Livestock Disease Atlas bases its analysis on the Livestock Units (LSU).  Each species has a LSU value, 
and the losses of LSU have been given a value.  See Figure 2. For more information on the methodology 
description, please refer to the World Bank Atlas itself (pages 6 & 7). HS is one of the top 10 diseases causing 
losses for cattle and buffalos, as shown in Figure 3. However, looking at the data in detail, there are few data 
from sub-Saharan Africa and Asia.  
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Figure 3: Top 10 diseases in terms of LSU losses for cattle, buffalo, and sheep & goats. Source: World 
Livestock Disease Atlas – The World Bank, 2011 [11]. 
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Treatment is of little use once signs of HS have appeared, but could be effective in the early stages (OIE, 2009). 
As HS is a primary bacterial disease with no other biological agents involved, treatment may appear simple using 
the wide range of antibiotics currently available. In reality, however, treatment is constrained by a host of 
practical considerations. It has been found in practice that animals can only be cured if they are treated in the 
very early stages of the disease. As the disease occurs mainly in situations with very basic husbandry practices 
most field cases escape detection in the early stages, thus rendering treatment ineffective. In organized farms, 
however, a practical method of achieving early detection and successfully treating animals is to check the rectal 
temperatures of all in-contact animals regularly once an outbreak has been detected. Any animals showing an 
increased temperature can be separated and treated with a course of an appropriate antibiotic. 
Generally, clinical cases of HS are extensively treated with oxytetracycline, co-trimoxazole, a combination of 
penicillin and streptomycin or sulphaquinoxaline. However, in the recent times, shifts in antibiotic sensitivity 
spectrum of P. multocida are evident and there have been increases in incidences of high morbidity and 
mortality. Compromised therapy may be due to emergence of multi-drug-resistant strains. A rise in multiple 
drug-resistant strains of P. multocida have been identified, especially for sulphadiazine, the drug of choice in the 
field for control of HS, as well as many other commonly used antibiotics such as amikacin, carbencillin, 
erythromycin and penicillin, where there is gradual development of resistance. Strains of P. multocida vary in 
susceptibility to chemotherapeutic agents. Most P. multocida isolates were resistant to sulpha drugs with varied 
sensitivity to chloramphenicol, gentamicin, tetracycline, kanamycin, penicillin-G, streptomycin, sulphonamides 
and trimethoprim as assessed by agar dilution and determination of the susceptibility of transconjugants and 
transformants by disc diffusion assay [6]. 
The injudicious use of antibiotics in developing countries is probably leading to the severe problem of antibiotic 
resistance, the genes of which may be on R-plasmids. Conjugative R-plasmids are commonly responsible for 
inter-species and intergenic spread of multiple drug resistance and transfer of such plasmids among pathogenic 
strains may give rise to epidemic spread of infection. Co-existence and the spread of small plasmids are used by 
P. multocida to become multi-resistant [6].  
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Sanitary measures include early detection and isolation of new cases and their immediate treatment with 
antibiotics, deep burial of carcasses or incineration, and the prevention of movements of animals to disease free 
areas.  Vaccination of susceptible animals in endemic areas is the only practical approach to prevent HS.  The 
different types of vaccines, and their advantages and disadvantages, are discussed in Section 6.  During an 
outbreak, the whole herd should be vaccinated, irrespective of previous vaccination history.  
 
Options and strategies for control programs at national, sub-national or regional level 
There are three categories of measures for prevention and control of HS (12) : 1- measures to be adopted in 
endemic countries on a prophylactic basis; 2- measures to be taken in the event of an outbreak; and 3- measures 
necessary for prevention of spread across regional or national borders. Eradication is also discussed.  
 
Measures to be adopted in endemic countries on a prophylactic basis: 
• Vaccinate on a routine prophylactic basis. Vaccination is best done two to three months before the high-
risk season (in areas where seasonality occurs) so as to ensure peak immunity during the period of 
maximum risk. 
• Establish a good reporting system. This will enable information on suspected outbreaks to reach animal 
health authorities as quickly as possible.  
• Create awareness of the disease among farmers. 
• Prevent mixing of animals from endemic and non-endemic areas. In endemic areas, a significant 
proportion of animals are latent carriers and are potential sources of infection. In non-endemic areas, 
animals are not regularly exposed to infection, lack naturally acquired immunity, are not usually 
vaccinated, and are highly susceptible. An outbreak originating from an activated carrier in such an 
instance can be explosive. If contact between such animals is unavoidable, it is of utmost importance 
that susceptible animals from non-endemic areas are vaccinated at least two weeks before contact 
withanimals from an endemic area. 
 
Measures to be taken in the event of an outbreak: 
• Continue vaccination programs. Vaccination is recommended even in the face of an outbreak. In such 
situations broth bacterins or the alum  precipitated (or aluminium hydroxide gel) vaccine is preferred. 
Broth bacterin and the oil adjuvant vaccine may be administered at different sites, simultaneously. 
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• Isolate and treat animals showing clinical signs with a parenteral broad-spectrum antibiotic (relatively 
easy in organized farms or herds that are paddocked at night or for part of the day). 
• Check the rectal temperature of all immediate in-contact animals in the herd. This should be done at 
least once every morning; those animals showing increased temperatures should be treated. 
• Search daily for sick animals or carcasses of dead animals (free-roaming, nomadic herds). 
• Confine herds as much as possible, and prevent movement of animals in and out of diseased premises or 
villages. 
• Take immediate action to carry out postmortem examinations (local veterinarians) and dispatch samples 
to the nearest diagnostic laboratory.  
• Dispose of carcasses of dead animals properly. Deep burial or effective incineration is recommended. 
Often, after animals die, carcasses are disowned by farmers. Stray dogs and other scavenging animals 
can disseminate infection by carrying away portions of infected carcasses, and carcasses dumped into 
streams and waterways are important sources of infection. 
• Properly dispose of unconsumed fodder, bedding etc. from infected premises. Deep burial or drying and 
burning should be carried out within the premises. Effluent from cattle sheds, dung etc. should be 
prevented from being washed away from the premises. Drains carrying such material should be led into 
a deep protected pit within the premises, or subjected to disinfectant treatment. 
• Closely monitor or stop rain-associated activities. Activities such as ploughing and preparation of fields 
for rice cultivation cause considerable movement of draught cattle and buffaloes, and they should be 
minimized. Might be very difficult for the farmers to stop these activities completely. HS often breaks 
out during wet seasons.  
 
Measures necessary for prevention of spread across regional or national borders: 
(note that this come from recommendations from De Alwis, 1999, and are not OIE guidelines) 
• Ensure that the animals originate from a region where no outbreaks of HS have occurred for a minimum 
of one year. How extensive this disease-free 'region' should be will depend on the system of 
management practiced in the region.  
• Bleed a random sample of animals. This should include the herd or farm of origin and/or other in-
contact animals. Test for the presence of antibody by the indirect haemagglutination (IHA) test. High 
antibody titres is an indication of recent exposure to the disease.  
• Hold animals under observation for two to three weeks before transport. During this time repeated 
attempts should be made to check nasopharyngeal swabs for pasteurellae by mouse inoculation and 
culture. Blood collected at the beginning and end of such a period should be checked for antibody by the 
• IHA test. Animals harbouring type B pasteurellae and/or showing IHA titres should be eliminated. The 
detection of any carriers or animals with antibody titres would justify an extended period of pre-
transport observation for other in-contact animals in the group. 
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• Quarantine animals after transport to the new location. The animals can be held for a similar period of 
time to that used before transport. During this time, the same procedures should be carried out. 
• Vaccinate animals from disease-free locations in endemic countries. A dose of oil adjuvant vaccine may 
be given at the end of the quarantine period, followed by a booster three months later. It is equally 
important to vaccinate all animals in the country of import that are likely to come into contact with 
animals introduced from endemic countries or regions. Vaccination is the most important control 
procedure adopted in all countries where the disease is endemic. 
 
Eradication 
No country has ever attempted to eradicate HS. This reflects the belief that the existence of carriers makes 
eradication too hard. This has been strengthened by recent findings indicating that a larger proportion of 
animals are carriers than was originally thought and that for most of the time the disease remains latent. The 
existence of carriers among feral ruminants may be a further factor that will make eradication difficult. The only 
known attempt at eradication was made by the Government of Indonesia on a pilot scale on the island of 
Lombok with a cattle population of 300,000. The program started in 1978 with intensive vaccination campaigns 
that were targeted to achieve the highest possible coverage in all susceptible species. The coverage actually 
achieved over a three-year period was 89% in cattle, 94% in buffaloes, 82% in goats, 93 % in sheep and 80% in 
pigs. The program was evaluated in 1981, after three annual vaccinations using the oil adjuvant vaccine. During 
this period, 53 cases of HS were reported. Culture of pharyngeal mucous membrane samples from 220 animals 
slaughtered in an abattoir yielded positive isolations from five animals (2.2%). Mass vaccination was continued, 
and a second evaluation was made in 1985. A total of 450 abattoir samples from cattle, buffaloes, goats and pigs 
were negative. Also, 103 specimens from animals suspected of HS were negative. This island was declared free 
of the disease in 1985. However, subsequent evaluations based on culture, serology and field reports indicate 
that HS is still present in Lombok. These observations provide useful indicators of the complexities involved in 
attempting a total eradication program for HS even on a small island; the implications are much more complex 
in countries with land borders and a large wildlife population. 
 
Disease situation and government policies by country:  
Tables 7 to 12 below have been completed with the information received from the questionnaires sent to the 
Director Generals and Department of Veterinary Services of the countries of interest.   
Tables 7 and 8 show the information received for HS, tables 9 and 10 the information received for Pneumonic 
pasteurellosis of cattle, and tables 11 and 12 for small ruminant pasteurellosis.  
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Table 7, 9 and 11 cover the disease situation (if it is notifiable or not), the presence of official surveillance and/or 
control programs, and the treatment situation.  Tables 8, 10 and 12 refer to the vaccination situation. 
 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination 
of information to those who need to know so that action can be taken.  
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a country for 
the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that country, 
or within a zone or compartment of that country. 
Table 7: Official status, official programs and treatment for Hemorrhagic septicemia in the countries of 






















Bangladesh Yes Yes, passive Yes (targeted) Yes Yes 
India      
Indonesia      
Myanmar (Burma) Yes Yes, passive Yes No Yes 
Nepal No Yes, passive No Yes Yes 
Vietnam Yes Yes, passive No Yes Yes 
AFRICA 
Burkina Faso      
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Côte d'Ivoire (Ivory 
Coast) 
Yes Yes, passive. But 
active in case of 
outbreaks 
Yes Yes When animals are 
sick 
Ethiopia      
Kenya No Yes, passive No Yes No 
Madagascar      
Malawi Yes No No Yes No 
Mali Yes Yes, passive Yes Yes Yes 
Mozambique      
Rwanda  - - - - - 
Senegal      
South Africa      
Tanzania  Yes Yes, passive No Yes No 
Uganda No No No N/A N/A 
Zambia Yes Yes, passive Yes Yes Yes 
 
Table 8:  Vaccination for Hemorrhagic septicemia in the countries of interest.  















Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
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Bangladesh No Combination 
(Government subsidy, 
owner pays service 
charge) 
Official Cattle and buffalo 
India     
Indonesia     
Myanmar 
(Burma) 
Yes Government Official Cattle 
Nepal No N/A N/A N/A 
Vietnam Yes Farmers Both Cattle, buffaloes, pigs 
AFRICA 
Burkina Faso     
Côte d'Ivoire 
(Ivory Coast)  
No Farmer - - 
Ethiopia     
Kenya No N/A N/A N/A 
Madagascar     
Malawi No N/A N/A N/A 
Mali No Combination Official Cattle 
Mozambique     
Rwanda - - - - 
Senegal     
South Africa     
Tanzania  No Not done Not done Not done 
Uganda No N/A N/A N/A 
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Zambia No Farmers Both Cattle 
 
-  Questionnaire received, but left blank by respondent. 
Table 9:  Official status, official programs and treatment for Pneumonic pasteurellosis in the countries of 






















Bangladesh No - - - - 
India      
Indonesia      
Myanmar (Burma) No No No No Yes 
Nepal No No No No No 
Vietnam No No No Yes Yes 
AFRICA 
Burkina Faso      
Côte d'Ivoire (Ivory 
Coast) 
Yes Yes, passive. But 
active in case of 
outbreaks 
Yes Yes When animals are 
sick 
Ethiopia      
Kenya No Yes, passive No Yes No 
Madagascar      
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Malawi No No No Yes No 
Mali Yes Yes, passive Yes Yes Yes 
Mozambique      
Rwanda  - - - - - 
Senegal      
South Africa      




Yes, active No No No 
Uganda No No No N/A N/A 
Zambia Yes Yes, passive Yes Yes Yes 
 
-  Questionnaire received, but left blank by respondent.  
Table 10:   Vaccination for Pneumonic pasteurellosis the countries of interest.  
















Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
Bangladesh - - - - 
India     
Indonesia     
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Myanmar (Burma) No - - - 
Nepal No N/A N/A N/A 
Vietnam No Farmers Both Pigs 
AFRICA 
Burkina Faso     
Côte d'Ivoire (Ivory 
Coast)  
No Farmer - - 
Ethiopia     
Kenya No N/A N/A N/A 
Madagascar     
Malawi No N/A N/A N/A 
Mali Yes Combination Official Cattle, sheep, goats, pigs 
Mozambique     
Rwanda - - - - 
Senegal     
South Africa     
Tanzania  No Not done Not done Not done 
Uganda No N/A N/A N/A 
Zambia No Famers Both Cattle 
 
 -  Questionnaire received, but left blank by respondent. 
Hemorrhagic septicemia | Monograph 17 






Table 11:    Official status, official programs and treatment for small ruminants pasteurellosis in the 























Bangladesh No - - - - 
India      
Indonesia      
Myanmar (Burma) No No No No Yes 
Nepal No No No No No 
Vietnam No No No Yes Yes 
AFRICA 
Burkina Faso      
Côte d'Ivoire (Ivory 
Coast) 
Yes Yes, passive. But 
active in case of 
outbreaks 
- - - 
Ethiopia      
Kenya No Yes, passive No Yes No 
Madagascar      
Malawi No No No Yes No 
Mali Yes Yes, passive Yes Yes Yes 
Mozambique      
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Rwanda  - - - - - 
Senegal      
South Africa      




Yes, active No No No 
Uganda No No No N/A N/A 
Zambia N/A N/A N/A N/A N/A 
 
 
 -  Questionnaire received, but left blank by respondent. 
Table 12: Vaccination for small ruminants pasteurellosis the countries of interest.  
















Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
Bangladesh - - - - 
India     
Indonesia     
Myanmar (Burma) No - - - 
Nepal No N/A N/A N/A 
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Vietnam No Farmers Both Sheep, goats 
AFRICA 
Burkina Faso     
Côte d'Ivoire (Ivory 
Coast)  
    
Ethiopia     
Kenya No  N/A N/A N/A 
Madagascar     
Malawi No N/A N/A N/A 
Mali Yes Combination Official Sheep and goats 
Mozambique     
Rwanda - - - - 
Senegal     
South Africa     
Tanzania  No Not done Not done Not done 
Uganda No N/A N/A N/A 
Zambia N/A N/A N/A N/A 
 
 -  Questionnaire received, but left blank by respondent. 
Hemorrhagic septicemia | Monograph 17 












Vaccines for the prevention of Hemorrhagic septicemia 
Simple toxoid vaccines for P. multocida protect relatively well, as those vaccines are based on the capsule of P. 
multocida. P. multocida usually has a prominent capsule, compared to the capsule of M. haemolytica which is 
well less developed.  
Bacterins: 
The OIE Terrestrial Manual (HS Chapter – updated 2012), says that effective vaccines against HS are formalin-
killed bacterins with adjuvants. The adjuvants enhance the level and prolong the duration of immunity. The OIE 
recommends to use a local isolate of P. multocida representing the prevalent serotype. Seed cultures for vaccine 
production should contain capsulated organisms. 
The commonly used HS vaccines are bacterins that are either alum-precipitated vaccines (APV), aluminum 
hydroxide (AlOH) gel vaccines or oil-adjuvanted vaccines (OAV).  To provide sufficient immunity with bacterins, 
repeated vaccination is required.  The use of multiple emulsion (ME) vaccines has been mentioned (the viscosity 
of OAV may be reduced by re-emulsifying it with an equal volume of Tween 80, producing a free flowing milk-
like liquid equivalent to that of a classical water-in-oil emulsion) [13], but no evidence of its use has been found.  
Very recently, Kumar et al published that a co-adjuvantation of an OAV with alum might be beneficial (so far, 
evaluated in mice). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662783/pdf/IJM-7-79.pdf.  
Administration of dense bacterins can give rise to shock reactions, which are less frequent with the APV and 
almost nonexistent with the OAV. The oil-adjuvant vaccine has not been popular because of difficulty in 
syringing. The alum-precipitated-type bacterin is given at 6-month intervals, while one dose of the OAV provides 
protection for 9-12 months. 
Live vaccines: 
A live HS vaccine prepared using an avirulent P. multocida strain B:3,4 (Fallow deer strain) has been used for 
control of the disease in cattle and water buffaloes over 6 months of age in Myanmar since 1989. Safety, efficacy 
and cross protection data has been published [14]. It is administered by intranasal aerosol application. The 
vaccine has been recommended by the Food and Agriculture Organization of the United Nations (FAO) as a safe 
and potent vaccine for use in Asian countries. It has also been evaluated recently in Pakistan, where it showed 
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that the vaccine could be given safely through aerosol route to buffalo calves 4 to 6 months old. A single dose 
would protect for only 7 months, but animals given a booster after one month, were protected after 12 months 
of vaccination [15]. Challenges after 12 months were not conducted in the study. However, there is no report of 
its use in other countries and killed vaccines are the only preparations in use by the countries affected with HS 
(OIE, 2012).  
Live candidate vaccines have been identified, as for example the live attenuated aroA mutant of P. multocida B:2 
strain developed by Dr. Tabatabei in Iran [16]. Efficacy has been published, but no information has been found on 
reversion to virulence. A live gdha derivative P. multocida B:2 has been developed and evaluated with promising 
results in Malaysia. See Section 8 for more details.   
Other HS vaccines: 
There are no vaccines for HS based on biotechnology (OIE, 2012). 
Comments on cross protection: 
The protective immunity for Pasteurella multocida resides in the capsule. The classification based on A B D and 
E  rests on the capsule, and there is very little, if any cross protection between capsule types.  In Asia, the only 
isolated serotype is B:2. In Africa, the predominant serotype is E:2, but some African countries have also 
reported B:2 (Egypt, Sudan, Cameroon, Namibia and Zimbabwe ).  
Cross protection between P. multocida B and E is limited.  For example, a study conducted with the two local 
Sudanese P. multocida strains B and E used for vaccine production, showed that there was a limited cross 
reaction between the two strains in the rabbit sera when tested by ELISA [17].  Vaccine of strain E protected 50% 
of the rabbits against challenge with strain B, while the vaccine of strain B could not protect the rabbits against 
the challenge with strain E (0%). Each vaccine of B and E could protect 100% of the rabbits against the challenge 
with the same strain. 
In an abstract of the Pasteruaceae conference in 2014 presented by Dr Harper, it is mentioned that while it is 
believed that bacterins provide excellent protection against strains of the same LPS serovar it has never been 
objectively tested. The group (based at Monash University in Melbourne) suggested the use of a PCR that groups 
the different strains into 8 LPS types.  When they did the LPS structural analysis (strains 3 and 6, the most 
commonly isolated in poultry), it revealed that many related, but structurally distinct, LPS glycoforms are 
produced by different isolates from within a single genotype. Moreover, in some L3 field isolates, multiple LPS 
glycoforms are simultaneously produced by the one strain. The existence of genetically related field isolates 
producing a wide range of LPS glycoforms, with some strains producing many glycoforms simultaneously, raises 
significant questions about the ability of existing P. multocida bacterins to elicit protection against even closely 
related strains  
http://pasteuraceae-2014.p.asnevents.com.au/days/2014-05-16/abstract/13035. 
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I contacted Dr Harper, who mentioned one of his PhD students has just finished looking at the sequences of HS 
strains, and they were all very clonal, and she did not believe there was too much difference between the 
strains.  Unfortunately, they only had available B strains from Pakistan, and didn’t have E strains from Africa, but 
she would think they are very clonal as well.  She facilitated the contact with Dr Blackall from Queensland 
University who is responsible for the Australian Reference centre for Pasteurellacea. He believes that LPS 
polymorphism is involved in vaccine failure in poultry (associated with killed vaccines), but does not have 
information on HS. More details on Section 7.   
Comments on vaccine potency: 
Gowrakkal et al [18] say that in spite of annual vaccination, outbreaks of HS are recorded every year, and that this 
may be due to improper vaccination and the use of a low potent vaccine. With the focus on potency, they 
compared the seed culture of HS bacteria used to produce the vaccine for its antibody induction efficiency, 
before and after passaging it in the natural host (calf).  They used the strain P-52, of the Indian Veterinary 
Research Institute, Izatnagar, Uttar Pradesh. The results revealed that back passaged vaccine seed, provided 
better immune efficiency than the original stock culture, and therefore recommend the back passaging of the 
seed vaccine at least once in 6 to 8 months in its natural host system for the induction of better immunity.  
The OIE does mention in the Terrestrial Manual “A calf is infected with the culture, and, within 2-3 hours of its 
death, blood is collected aseptically from the heart and stored at -20°C in 1 ml aliquots.  A fresh aliquot is used 
for each new batch of vaccine.  It is permissible to subculture this aliquot once or twice, provided the colony size 
does not diminish”.  I have discussed this procedure with Dr Nwankpa from AU-PANVAC who believes most 
African laboratories produce their master seed in calves and if the seed gets too old (over 2 years), then they 
passage it again in calves.   
For more details on the different HS vaccines, please see Table 12.  
 
Vaccines for the prevention of Pneumonic pasteurellosis in cattle (caused by M. haemolytica and P. multocida) 
The initial M. haemolytica vaccines, being simple toxoids had 2 limiting factors. First, there is no cross-protection 
between serotypes, and the more serotypes were included, the poorer the protection against all strains. Five 
strains were the maximum number that could be included.  The second limiting factor was the endotoxin level, 
which induced shock reactions, and paradoxically, an exacerbation of the pneumonia.  
Virulence factors were investigated, and leukotoxins (Lkt) were identified. M. haemolytica produces an exotoxin 
(Lkt) during the logarithmic phase growth, that binds to the intact signal peptide of CD18 on bovine leukocytes, 
and lyses them. The Lkt from cattle is relatively homogenous. It is Important to note that the leukotoxin does 
not protect against P. multocida infections.  
Other vaccines have been developed based on iron regulated proteins, and outer membrane proteins (OMP) 
which are associated with iron regulation. The iron-regulated proteins are related to the serotype. A better 
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protection is shown if the iron-regulated outer proteins are derived from a number of different strains, and 
there is some cross-protection between unrelated strains. More strains can also be included in the vaccine than 
in a bacterin vaccine.   
Modern vaccines use culture supernatants containing leukotoxin (Lkt) and other soluble antigens, or bacterial 
extracts, alone or combined with bacterins.  Some people says Lkt based vaccines, protect cattle well against 
nearly all M. haemolytica infections. Some other say that these modern vaccines have 50–70% efficacy in 
prevention of M. haemolytica pneumonia [2]. There are no OIE standards for M. haemolytica vaccines.   
 
Vaccines for the prevention of pasteurellosis in small ruminants (caused by M. haemolytica and B. trehalosi) 
Sheep are affected by all 17 of the original P. haemolytica serotypes (now known as M. haemolytica, and some 
as B. trehalosi) and because their strains show much more variability between different strains of any single 
serotype, they are not protected as well as cattle are, by leukotoxin type vaccines. Serotyping does not indicate 
whether a particular strain isolated from sheep would protect that sheep if a Lkt vaccine would be used. The 
leukotoxin vaccines are based on the cattle M. haemolytica A1 strain of the Lkt, which may be the same or may 
differ from the Lkt of the strain which is infecting the sheep. This explains the variability in protective effect 
when sheep are vaccinated with Lkt vaccines (commercial vaccines for sheep are still usually based on the 
serotype, and not on Lkt). 
This can be exemplified by a contact I had from an African vaccine manufacturer requesting help for a case of 
pasteurellosis in goats, in which the vaccine was not effective, and due to their limited diagnostic capability, they 
were not able to serotype.  
A large multinational pharmaceutical company produces a vaccine for sheep based on iron-regulated proteins 
which contains 9 serotypes and is available in South Africa. This vaccine provides a broader protection. The 
amount of cross protection cannot be determined precisely, as there is a complex combination or virulence 
factors in sheep strains.  
 
Main vaccine needs 
There is a need for a vaccine that has/is: 
• Longer duration of immunity.  
• Easier to administer 
• More cross-protective (especially in some African countries, where both strains have been identified) 
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Aluminum hydroxide gel Oil adjuvant vaccines
 (OAV)
B:3, 4
Status Extensively used in 
different parts of the world
Thailand and Laos, but also 
other countries in Asia and 
Africa.
Extensively 
commercialized in Asia. 
Also sold in Africa.
Used in Myanmar
Type Killed Killed Killed Live
Origen Bacterin to which potash 
alum has been added to 
have a 1% final 
concentration
Aerated cultures blended 
with AlOH gel at a final 
concentration of 3%
Strain isolated from a fallow 
deer in England (P. multocida 
strain B: 3,4)
Target species Cattle, sheep and goats Cattle and buffaloes Cattle and buffaloes Cattle and water buffaloes
Indications Vaccinate animals 6 
months of age and above.
6 months of age or above, 
followed by booster dose 
after 1 month. Other 
manuf say from 2 weeks of 
age. 
Vaccinate at 3-4 months of 
age with 2 doses at 3 
months interval
For use in animals over 6 
months of age
Immunity 6 months 4 - 6 months. 1 year but has been 
reported 18 months in 
buffaloes, and 26 months 
in cattle.
1 year
Route SC SC IM IN (fine aerosol)
Dose & volume Approx 0.75 µg dry weight 
per ml, so that a 3 ml dose 
has minimum 2 µg bacteria.  
(5 - 10 ml for cattle & 
buffaloes depending on 
the size of the animal)
2 ml for all age groups of 
cattle and buffaloes. 1 ml 
for all age groups sheep 
and goats.
If a  3-mL dose is to be 
used, the minimum 
requirement of 2 µg dry 
bacteria should be present 
in 1.5 mL .  Some 
manufacturers use a 2 ml 
dose.










No No No No
Use in pregnant 
animals
Just as precaution, it is 




Shock reactions can occur Small lump may develop at 
injection site, and animals 
may show temporary 
lameness.
Difficult to inject due to 
high viscosity. Abscess at 
the site of injection and 
vaccination reactions often 
reported
First used 1950s 1984
Large scale use Extensively used in 
Southern India and Central 
Africa. Most popular is 
some Asian countries.
In Myanmar has been used 
since 1989
Others Important to mix 
thoroughly because alum 
causes the cells to settle at 
the bottom 
Shake well before use. Superior in terms of 
storage at room 
temperature for 1 year 
without deterioration
FAO has recommended it for 
use in other Asian countries, 
however, there are no reports 
of it being used.
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The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers.   
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders.  
While efforts have been made to encompass them, the TPP showed in Table 12 below, should be considered a 
proposal, a live document subject to improvements.  
 
Information on current vaccines has been obtained from the datasheet of different products as per links below: 
APV: http://ivpm.webs.com/products.htm  
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Table 14:   Target Product Profile (TPP) Hemorrhagic septicemia vaccine – Proposal: 
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen 
 
Immunogen with protective antigens 
for P. multocida B (Asia) or E (Africa) 
Immunogen with protective antigens for 
P. multocida B (Asia) and B &E (Africa) 
2 Indication for use For active immunization of cattle, 
buffaloes, sheep and goats.   
 
For active immunization of cattle, 
buffalo, sheep and goats of all ages and 
sexes.  
3 Recommended species 
 
Cattle, buffalo, sheep and goats Cattle, buffalo, sheep and goats.  
4 Recommended dose 
 
APV: 5 – 10 ml (depending animal size) 
AlOH: 5 ml 
OAV: 2 – 3 ml 
Live: 2 x 107 viable organisms/dose 
Same dose for all species (2 ml) 






Ready to use solution/suspension 





Live:  IN 
SC, IM or fine aerosol  
7 Regimen - primary 
vaccination 
APV: single vaccination 
AlOH:  Booster 1 month. 
AOV: Booster 3 months 
Live: single vaccination 
Single lifetime dose 
8 Regimen - booster APV:  
AlOH: 6 – 12 months (one month 
before expected occurrence)  
Lifelong immunity after primary 
vaccination 
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AOV: Annual (one month before 
monsoon) 
9 Epidemiological relevance Protection against Hemorrhagic 
septicemia 
Protection against Hemorrhagic 
septicemia 
10 Recommended age at first 
vaccination 
APV: 6 months 
AlOH: 6 months. Some manufacturers 
say from 2 weeks.  
OAV: 3- 4 months 
Live: Over 6 months of age 
From 1-2 months of age, when other 
vaccines are applied.  
11 Onset of immunity 
 
APV:  
AlOH: 2 weeks 
OAV:  21 days 
Live: 
One week following primary vaccination 
12 Duration of immunity 
 
APV: 6 months 
AlOH: 4 – 6 months 
OAV: 1 year 
Live strains: 1 year 
Lifelong immunity 
13 Expected efficacy To prevent disease & prevent 
mortality. 
To prevent infection and transmission in 
100% of the animals.  
14 Expected safety APV:  
AlOH: Occasionally, transient swelling 
at site of injection.  
OAV: Small swelling at injection site. 
Live: reactions when used SC or IM. 
Safe when used IN.  
No post-vaccinal reactions at any age.  
 
15 Withdrawal period 
 
APV:  
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16 Special requirements for 
animals 
Do not vaccinate un-healthy animals 
or during an outbreak. 
Vaccinate all animals 
17 Special requirements for 
persons 
  None 
18 Package size 
 
APV: 50 doses 
AlOH: 20 – 50 doses 
OAV: 150 doses 
Live strains: 
Multiple pack size from 5 doses 
19 Price to end user 
 
  
20 Storage condition and 
shelf-life as packaged for 
sale 
APV: 21 days at room temperature, 6 
months at 4°C.  
AlOH: Stable at 2-8°C for 2 years 
OAV: Stable at 4-8°C for 1- 2 years 
Live strains: 
Stable at 30°C for 24 months 
 






24 hours or greater 
22 Other:     
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Scientific quality: The publications and data from the different research groups, should be carefully evaluated.  
The use of good science and good experimental design with use of proper controls, adequate numbers, suitable 
challenge model, reproduction of results by them and by independent groups, and appropriate analysis has not 
been verified for this monograph.  If any of these projects were to be pursued, a detailed peer review taking into 
account the above considerations is strongly recommended.   
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ANNEX 1:  Phylogenetic relationships of Pasteurella 
multocida and related Pasteurellaceae bacteria 
based on 16S rRNA genes.  
 
Source: Wilson and Hoi, 2013 [1].  
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ANNEX 2:  Revised names for genus Pasteurellaceae 
 
New Name Old Name Old Serotype 
Mannheimia haemolytica Pasteurella haemolytica 1, 2, 5, 6, 7, 8, 9, 12, 13, 14, 16 
Mannheimia glucosida Pasteurella haemolytica 11 
Mannheimia rumenalis Pasteurella haemolytica Untypable 
Mannheimia granulomatis Pasteurella granulomatis Untypable 
Mannheimia varigena Pasteurella haemolytica 6, 14 
Mannheimia taxon 7 Pasteurella haemolytica Untypable 
Mannheimia taxon 8 A, B & C Pasteurella haemolytica Untypable 
Mannheimia taxon 9 Pasteurella haemolytica Untypable 
Mannheimia taxon 10 Pasteurella haemolytica Untypable 
Mannheimia taxon 12 Pasteurella haemolytica Untypable 
Biberstenia trehalosi Pasteurella haemolytica 3, 4, 10 & 15 
 
Pasteurella multocida did not change the name.  
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ANNEX 3: Additional data on disease presence and 
incidence 
 
Reports to OIE on Hemorrhagic septicemia: 
 
 
When different animal health statuses between domestic and wild animal population are provided, the box is split in two: 
the upper part for domestic animals, and the lower part for wild animals.  
 
Hemorrhagic septicemia in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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Hemorrhagic septicemia in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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Hemorrhagic septicemia in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
 
 
 
 
 
